研究单位：[1]Tongji Hospital in Wuhan[2]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[3]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230032[4]Fujian Provincial cancer Hospital,Fuzhou,Fujian,China,350009[5]Zhongnan Hospital of Wuhan University,Wuhan,Hebei,China,430071[6]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[7]Henan Provincial Cancer Hospital,Zhengzhou,Henan,China,451100[8]The Affiliated Hospital of Xuzhou Medical College,Xuzhou,Jiangsu,China,221000[9]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China,330029[10]Linyi Cancer Hospital,Linyi,Shandong,China,276000[11]Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,Shanghai,China,200092[12]Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chongming Branch,Shanghai,Shanghai,China,202150[13]Tangdu Hospital,Xian,Shanxi,China,710038[14]Tumor Hospital of Yunnan Province The Third Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650118
This is a multicenter, randomized, double-blind , placebo-controlled trail to investigate the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.
